CIA
SRPT icon

Caerus Investment Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Caerus Investment Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$214K Sell
9,854
-8,368
-46% -$162K 0.09% 232
2025
Q4 		$392K Buy
+18,222
New +$384K 0.13% 181

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Caerus Investment Advisors's SRPT Position: Q1 2026 in Review

Caerus Investment Advisors reduced its Sarepta Therapeutics (SRPT) stake by 46% in Q1 2026, selling an estimated $162K and leaving 9,854 shares worth $214K. The position accounts for 0.09% of the portfolio, ranked #232.

Caerus Investment Advisors first reported a position in SRPT in Q4 2025 and has held it in 2 quarters since. The position peaked at $392K in Q4 2025. 340 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • Caerus Investment Advisors held 9,854 shares of Sarepta Therapeutics worth $214K as of Q1 2026.
  • Caerus Investment Advisors sold 8,368 Sarepta Therapeutics shares in Q1 2026, an estimated $162K.
  • Sarepta Therapeutics made up 0.09% of Caerus Investment Advisors's portfolio in Q1 2026, its #232 holding.
  • Caerus Investment Advisors first reported a position in Sarepta Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Caerus Investment Advisors's Sarepta Therapeutics position peaked at $392K in Q4 2025.
  • 340 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Caerus Investment Advisors's 13F filing for Q1 2026, filed 1 Jun 2026.